Fennec Pharmaceuticals (FENC) said Thursday it made the early repayment of $13 million of its roughly $32 million outstanding convertible debt facility with Petrichor Healthcare Capital Management.
The company used available cash to fund the repayment. The remaining $19 million will mature in September 2027.
Fennec said it expects its cash, cash equivalents and investment securities to be enough to fund planned operations into 2026.
The company's shares were down 0.7% in recent trading.
Price: 5.62, Change: -0.04, Percent Change: -0.71
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.